-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 10, local time, the Norwegian Radio and Television Company (NRK) reported that the Norwegian study pointed out that there is a link between the AstraZeneca vaccine and thrombosis, but researchers still do not know which substances in the vaccine can trigger this side effect.
The study was published in the "New England Journal of Medicine" on the 9th.
Ingvild Srvoll, chief physician of the UNN research team in Tromsø, said: "This is a drug side effect, in which antibodies against heparin drugs are formed.
Madsen, the medical director of the Norwegian Medicines Agency, said that it is not yet known what triggers this side effect, so this study is very important and provides a basis for further research.
Madsen said the study will influence the decision of the Norwegian Institute of Public Health (FHI) whether to re-vaccinate AstraZeneca.
It is reported that Norway stopped vaccinating AstraZeneca's new vaccine in early March, and the Norwegian Institute of Public Health will announce on April 15 whether to re-vaccinate AstraZeneca.
